Global menu

Our global pages


Eversheds advises leading life sciences software firm on its sale to US company

  • USA


    Law firm Eversheds has advised US private equity firm Accel-KKR and the principal shareholders of Zinc Ahead on its sale to Veeva Systems for cash consideration of $130 million.

    Zinc Ahead is a portfolio company of Accel-KKR, it is headquartered in Oxford, UK and has approximately 180 employees. Zinc is a leading provider of marketing compliance and approval software-as-a-service solutions to the life sciences industry. More than 50,000 marketing, medical and legal professionals currently use Zinc’s products across 120 clients in 170 countries.

    Veeva is a NYSE-listed California headquartered provider of cloud-based software to the global life sciences industry.

    The Eversheds team was led by partner Richard Moulton, assisted by senior associate Andrew Overend and associate Alex Pritchard. Principal associate Emma Tierney advised on commercial aspects and senior associate Colin Askew provided tax advice.

    Richard commented:

    “Having advised Zinc on its initial growth equity investment from Accel-KKR in 2013, it is a real pleasure to now have advised the Zinc shareholders on its sale to Veeva. Zinc is a highly innovative and progressive company who continue to go from strength to strength and we wish them every success.”

    James Brown, CEO and co-founder of Zinc Ahead, said:

    “Eversheds are experts in their field who completely understand our business. The team worked tirelessly to get this deal over the line and we are extremely grateful for their continued advice and support.”


    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back

    Print Friendly and PDF
    Register to receive regular updates via email.